Roche 'good' cholesterol drug shows promise
London, August 22, 2011
An experimental drug from Roche, a Swiss global healthcare company, designed to raise "good" HDL cholesterol has produced encouraging results in a small mid-stage clinical trial.
Further details about the performance of dalcetrapib will be released at a medical meeting in Paris next week, but analysts said a scientific abstract posted by the European Society of Cardiology at the weekend painted a positive picture.
While dalcetrapib continues to be viewed as a high-risk project, its chances of success have improved following data from the 130-patient Phase II imaging study, showing it does not increase plaque-related inflammation on artery walls.
Furthermore, patients on the new drug had less build-up of potentially artery-clogging plaque in their blood vessel walls than those on placebo, and the medicine was well tolerated.
It is still early days for dalcetrapib, and medical experts remain wary following the high-profile failure of a similar drug from Pfizer called torcetrapib. There is also a lack of evidence -- so far at least -- that raising HDL with drugs actually stops heart attacks and strokes.
But analysts believe the medicine could become a major seller if it proves itself in final-stage Phase III tests.
Roche will have to wait for results from a much larger clinical study at the end of 2012 to see whether its medicine produces a real benefit in clinical outcomes. Still, the early signs are encouraging, with only two cardiovascular events among patients on dalcetrapib seen in the small Phase II trial, compared with 13 among those on placebo.
Andrew Weiss, an analyst at Vontobel, currently gives dalcetrapib a 30 percent chance of success but believes the medicine could generate peak sales of 4 billion Swiss francs ($5.1 billion), if it works.
That would make it a major product for Roche and one that would start to diversify its focus firmly beyond cancer treatments, where it is the market leader.
However, dalcetrapib will not make its mark for a few years, and industry analysts, on average, are forecasting only a modest $203 million in annual sales by 2015, according to Thomson Reuters Pharma.
Merck & Co also has a competitor in the HDL-raising drug race, known as anacetrapib. -Reuters
More Health & Environment Stories
- The age of genomic medicine dawns, finally
- Over 300 exhibitors for Saudi healthcare event
- Mackeen unveils document management solution
- Seha opens new clinics in Abu Dhabi, Al Ain
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman
- Al Noor Hospitals targets domestic growth
- Medical panel on the way in Bahrain
- 40pc of UAE adults ‘have hypertension’
- Saudi diabetics urged to stay away from camels
- GCC readies plan to fight heart diseases
- Bahrain opens sickle cell hospital
- Hazardous waste focus for Oman summit
- Infectious viruses to be tracked by satellite in UAE
- Mafraq Hospital names new surgery chief
- Saudi health ministry seals BMJ partnership
- Need for medical simulation training highlighted